Streetbeat News

Products Services

NDRA

ENDRA Life Sciences Inc. (NASDAQ:NDRA) has announced the issuance of five new international patents, enhancing its intellectual property portfolio to 80 issued patents globally. These patents, including three in Europe and two in China, protect the company's Thermo Acoustic Enhanced UltraSound (TAEUS) technology, offering potential for growth through licensing opportunities and applications beyond its core focus.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:08 pm

ALUR

Allurion Technologies, Inc. (NYSE:ALUR) announced its participation in the IFSO-European Chapter 2024 with three presentations showcasing the long-term effectiveness of its weight loss program and the initial positive outcomes of its AI-powered conversational agent, Coach Iris. The data revealed 80% sustained weight loss over three years and high satisfaction rates with Coach Iris, emphasizing its personalized and trustworthy approach.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:08 pm

NRDY

Franklin County School District has entered into a partnership with Nerdy's Varsity Tutors to offer live and on-demand learning resources to all its students. This collaboration aims to enhance the educational experience by providing accessible and comprehensive learning tools.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:07 pm

ALLR

Allarity Therapeutics' shares surged following the announcement of positive results from the Phase 2 trial of Stenoparib in advanced ovarian cancer, leading to an early conclusion of the trial.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:04 pm

K

Kellanova reaffirmed its 2024 financial guidance, initially provided in August 2023, maintaining its projections despite adverse foreign exchange rates and industry volume pressures. The company expects organic net sales growth of 3% or better, an adjusted operating profit of $1,850-1,900 million, adjusted EPS of $3.55-3.65, and a free cash flow of approximately $1.0 billion, driven by priority snacks brands and emerging markets expansion, particularly with Pringles.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:03 pm

ARQQ

Arqit Quantum Inc. and SoftIron have announced a partnership aimed at facilitating a seamless transition for customers to quantum-safe cloud tasks, with a particular emphasis on serving the defense sector. This collaboration is expected to enhance security measures for cloud computing in sensitive areas, leveraging Arqit's quantum encryption technology.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:58 am

TM

Toyota Motor Corp (NYSE:TM) has rebranded its California R&D office as the North American Hydrogen Headquarters (H2HQ), emphasizing its commitment to hydrogen fuel cell technology. The H2HQ will centralize Toyota's hydrogen projects, including R&D, commercialization, and sales. This move is part of Toyota's broader strategy to lead in zero-emission technology and diversify fuel options beyond battery electric vehicles, reflecting its belief in customer-driven transportation solutions.

Portfolio Pulse from Anan Ashraf

May 02, 2024 | 11:58 am

ACXP

Acurx Pharmaceuticals announced the presentation of its Phase 2 trial results for Ibezapolstat at the ESCMID Global 2024 Scientific Conference. This marks a significant milestone in the drug's development process, potentially impacting the company's stock as investors react to the trial outcomes.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:57 am

FDX

SHYF

Shyft Group has received a purchase order from FedEx for an initial order of 150 Blue Arc EV trucks, marking a significant step into the electric vehicle market for both companies.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:54 am

LUCD

PAVM

Lucid Diagnostics, a subsidiary of PAVmed, announced positive results from a National Cancer Institute-sponsored study on EsoGuard, a test for esophageal precancer. The study, published in the American Journal of Gastroenterology, showed EsoGuard's high sensitivity in detecting early precancer, particularly in short-segment cases. These results support Lucid's efforts to secure commercial and Medicare payer coverage for EsoGuard. The company plans to seek Medicare coverage based on this data, aiming to provide a noninvasive, efficient screening method for esophageal cancer prevention.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:54 am